Formulations for the Suprachoroidal Space of an Eye and Methods
AssigneesEmory University, Georgia Tech Research Corporation
InventorsMark R. Prausnitz, Bryce Chiang
Life of this patent
Estimating the term…
Abstract
Provided herein are fluid formulations for administration to a suprachoroidal space of an eye of a patient. The fluid formulations may include a pharmaceutical agent, a binding molecule, or a combination thereof. The pharmaceutical agent and the binding molecule may be bonded to each other covalently, non-covalently, or a combination thereof. The pharmaceutical agent may be configured to bond to an ocular tissue. The binding molecule may be configured to bond to an ocular tissue. Methods of administering the fluid formulations, methods of expanding a suprachoroidal space, and methods of reducing the minimum force to separate the sclera and choroid are provided.
Claims48
A fluid formulation for administration to a suprachoroidal space of an eye of a patient comprising:
- a pharmaceutical agent and a binding molecule to which the pharmaceutical agent is covalently bonded, non-covalently bonded, or a combination thereof;
- wherein the pharmaceutical agent and the binding molecule together have (i) a hydrodynamic radius of at least 7 nm, (ii) a combined molecular weight of at least 500 kDa, or (iii) a combination thereof.
(canceled)
15-16. (canceled)
23-25. (canceled)
A fluid formulation for administration to a suprachoroidal space of an eye of a patient comprising:
- a pharmaceutical agent and a liquid medium in which the pharmaceutical agent is dissolved;
- wherein the formulation is configured to release the pharmaceutical agent from the formulation controlled by the rate at which the pharmaceutical agent partitions from the liquid medium into an ocular fluid of the suprachoroidal space.
A fluid formulation for administration to a suprachoroidal space of an eye of a patient comprising:
- a pharmaceutical agent comprising at least one feature that is configured to bond the pharmaceutical agent to an ocular tissue, thereby slowing the rate of clearance of the pharmaceutical agent from the suprachoroidal space;
- wherein the pharmaceutical agent is configured to bond to the ocular tissue covalently, non-covalently, or a combination thereof.
31-32. (canceled)
A fluid formulation for administration to a suprachoroidal space of an eye of a patient comprising:
- a binding molecule having (i) a hydrodynamic radius of at least 7 nm, (ii) a molecular weight of at least 500 kDa, or (iii) a combination thereof;
- wherein the binding molecule is configured to bond to a material in the suprachoroidal space covalently, non-covalently, or a combination thereof, to delay or prevent an interaction of the material with another material in the eye.
38-40. (canceled)
A method of expanding a suprachoroidal space of an eye, the method comprising:
- inserting a microneedle into the eye at an insertion site;
- and then
- infusing through the microneedle into the suprachoroidal space a first liquid formulation having a volume and viscosity sufficient to expand at least a portion of the suprachoroidal space to a thickness of about 500 μm to about 3.0 mm for at least two hours after the infusing.
(canceled)
A method of enhancing the delivery of a pharmaceutical agent or device to a suprachoroidal space of an eye of a patient, the method comprising:
- inserting a microneedle into the eye at an insertion site;
- infusing through the microneedle into the suprachoroidal space a volume of a liquid formulation sufficient to reduce by at least 25% the minimum force to separate the sclera and choroid;
- and then
- disposing a pharmaceutical agent or a device in the suprachoroidal space via the insertion site.
Dependencies are inferred from the claim text.